vandetanib + cisplatin

**Vandetanib + cisplatin** is an investigational combination therapy comprised of two pharmaceutical agents: vandetanib, a small molecule multi-target tyrosine kinase inhibitor, and cisplatin, a platinum-based chemotherapeutic DNA crosslinker. Vandetanib selectively inhibits vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases, impacting angiogenesis, cell growth, and survival; it has shown preclinical efficacy in overcoming cisplatin resistance and radioresistance. Cisplatin acts by forming covalent DNA adducts, resulting in DNA crosslinks that disrupt replication and transcription, leading to cell death[1][4][5][6][7]. This combination has been studied primarily in non-small cell lung cancer and head and neck squamous cell carcinoma settings, particularly to overcome resistance to standard chemoradiotherapy[1][4][5][7].